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Abstract A cyclic peptide analogue of platelet-derived growth 
factor-BB (PDGF-BB), PI |77IVRKK81-C-73RKIE781, has 
recently been shown to inhibit specifically |125I]PDGF-BB/ 
receptor binding, and PDGF-BB-induced DNA synthesis in cells 
expressing PDGF receptors. Here we demonstrate that PI 
induces apoptosis in exponentially growing human fibroblasts as 
confirmed by characteristic changes in cell and nuclear 
morphology, by TUNEL staining and by flow cytometry. 
Following incubation with PI (100 uM), the percentage of cells 
exhibiting DNA fragmentation increased from 24% after 8 h to 
76% after 28 h as exponentially growing cells progressed through 
the cell cycle. We conclude from these findings taken together 
that apoptosis accounts for the major proportion of Pl-induced 
cell death. Omission of the Cys residue from PI or replacement 
by Ser did not alter the potency of the peptide confirming that 
peptide dimerisation is not important for its activity. PDGF-BB, 
EGF, FGF, thrombin and foetal bovine serum were not able to 
rescue cells from the effects of PI. PI is a useful tool for 
investigation of the balance of cellular proliferation/apoptosis in 
wound healing, atherosclerosis and restenosis, and constitutes a 
basis from which to design compounds with greater potency. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
In tissues capable of self-renewal cellular proliferation exists 
in a regulated equilibrium with cell death, the latter occurring 
frequently via apoptosis [1,2]. A demonstration of this equi-
librium has been made in arteries following balloon injury in 
which smooth muscle cell (SMC) content has been observed 
to increase by only 10% of the cell number predicted from the 
rate of cell proliferation [3]. This discrepancy may be ex-
plained by the concurrence of cell death alongside prolifera-
tion [3-6]. Apoptosis as a mode of cell death in the arterial 
vessel wall has been demonstrated in studies of SMC death in 
human atherosclerotic lesions [6-8], and following balloon 
injury [8,9]. In vivo, immune cytokines including interferon-y 
(IFN-y), tumour necrosis factor-a (TNF-oc) and interleukin-lß 
may initiate SMC apoptosis [10], with protection from apop-
tosis being supplied by survival factors [11], or through inter-
actions of SMC with the extracellular matrix [12,13] or endo-
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thelial cells at the luminal surface [8,9]. Although the 
molecular basis of apoptosis is largely unknown, events orig-
inally considered to be solely associated with the induction of 
cellular proliferation, for example receptor phosphorylation 
[14] and activation of transcription factors including c-myc 
[15,16], c-fos [17] and c-jun [18], have recently been shown 
to occur during apoptosis. Development of agents which re-
duced the cellular proliferation associated with atherosclerosis 
and restenosis by triggering apoptosis would have therapeutic 
potential. 
Platelet-derived growth factor (PDGF) is a major connec-
tive tissue cell mitogen and chemotactic factor [19,20] which 
has roles in normal development [21,22], wound healing [23] 
as well as in several aberrant conditions including atheroscle-
rosis and fibrosis [19,24]. The mitogenic biological activity of 
PDGF isoforms, homo- and heterodimers of A- and B-chains 
is mediated through binding to a and ß cell surface receptor 
subunits initiating dimerisation of transcellular domains to 
homo- and heterodimers (reviewed in [25]). High affinity re-
ceptors for growth factors including PDGF activate cellular 
tyrosine kinases leading to subsequent receptor autophospho-
rylation and ultimately induction of transcriptional activators 
and subsequent cellular proliferation [25,26]. 
Recently we reasoned that cyclisation of peptides corre-
sponding to PDGF-BB73-81 (loop III) would generate com-
pounds capable of mimicking more closely the natural con-
formations of this region within PDGF-BB [27] whilst also 
reducing the conformational entropic penalty barrier observed 
in receptor/peptide interactions [28,29]. Cyclic PDGF7 3 - 8 1 
(PI) acts as a potent inhibitor of PDGF-BB-induced DNA 
synthesis in human fibroblasts and competitively inhibits the 
binding of PDGF-BB but not epidermal growth factor (EGF) 
to each of the two respective cellular receptors. The inhibitory 
action of PI upon DNA synthesis is restricted to cells express-
ing PDGF receptors as the peptide had no effect upon the 
PDGF receptor-negative cell lines A431 and COS-1 [27]. 
In the present work we establish that PI is able to induce 
apoptosis in human fibroblasts, an event which is not depend-
ent upon peptide dimerisation. PDGF-BB and other growth 
factors likely to be present in the microenvironment of the 
damaged vessel wall in atherosclerosis and restenosis are not 
able to rescue cells from Pl-induced apoptosis. We also pro-
vide evidence that high concentrations of PDGF-BB may also 
induce cell death and DNA fragmentation in human fibro-
blasts. 
2. Materials and methods 
2.1. Materials 
All chemicals were of the highest grade and were from Sigma 
Chemical Company Ltd., Poole, UK, unless stated. Other materials 
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suppliers were: peptide synthesis reagents (PerSeptive Biosystems, 
Hertford, UK), tissue culture reagents (Life Technologies Ltd., Pais-
ley, UK), plastics [Falcon] (Marathon Laboratory Supplies, London, 
UK), mefhyl-[3H]thymidine (1.85 TBq/mmol) (ICN Biomedicals Ltd., 
Thame, UK), recombinant human PDGF-BB, EGF and fibroblast 
growth factor (FGF, 146-amino acid isoform) (R&D Systems Europe 
Ltd., Abingdon, UK), thrombin (gift from Dr. J-M. Freysinnet, Uni-
versity Louis Pasteur de Strasbourg), ethidium homodimer and cal-
cein AM (Molecular Probes Inc., Eugene, OR, USA), fluorescent 
mounting medium (Dako Corporation, California, USA), fluorescein 
apoptosis detection kit (Promega, Southampton, UK), propidium io-
dide solution (Coulter Electronics Ltd., Luton, UK) and Vectashield 
mounting medium with 4,6-diamidino-2-phenylindole (DAPI) from 
Vector Laboratories Inc., California, USA. The HFFF2 cell line (hu-
man dermal fibroblast) was from the European Tissue Culture Col-
lection, Portón Down, UK, and was maintained in complete DMEM 
(DMEM supplemented with 4 mM L-glutamine, 100 IU/ml penicillin 
and 100 |xg/ml streptomycin) as previously reported [27]. 
2.2. Peptide synthesis 
Pep tides were synthesised as previously reported [27]. The purity 
and peptide content were determined by analytical RP-HPLC and 
ESI mass spectrometry. The cyclic peptides and corresponding 
PDGF-BB residue numbers used in this study were: 77IVRKK81-C-
73RKIE76 (PI), 77IVRKK81-73RKIE76 (P2) and 77IVRKK81-S-
73RKIE76 (P3). A linear peptide 73RKIEIVRKK81-C (P4) was also 
synthesised. 
2.3. The effects of peptides on DNA synthesis 
Previously reported methodology was used [27] except that 0.2% 
FBS was used in growth arrest medium. Coaddition to cells of pep-
tides was with PDGF-BB (15 ng/ml, 0.5 nM), EGF (1 ng/ml, 0.167 
nM), FGF (1 ng/ml, 0.063 nM) or thrombin (4 U/ml), added at time 
zero. Inhibition of DNA synthesis was expressed as reduction in 
[3H]thymidine calculated as a percentage of stimulation observed in 
the absence of peptide. Three different synthetic batches of PI were 
shown to inhibit PDGF-BB-induced DNA synthesis with a mean 
EC5o of 5.27 |xM (± S.D. = 2.3 uM), in general agreement with the 
previously reported value of 9.5 uM [27], 
2.4. Discrimination of live and dead cells by microscopy 
HFFF2 cells were grown to 40% confluence (2 days) on coverslips 
and the medium was replaced by complete DMEM containing 8% 
FBS together with PI (100 |J.M), and cultured continued for 8 h. 
Coverslips were then washed with PBS (3x2 min) and incubated 
under PBS containing 4 uM ethidium homodimer and 3 |lM calcein 
(30 min). Cell-permeant calcein AM is converted to fluorescent calcein 
by intracellular esterases within viable cells, whilst ethidium homo-
dimer only enters dead cells giving a red fluorescent staining of nucleic 
acids [30]. After washing with PBS (2X3 min) and distilled water 
(1x2 min), coverslips were mounted and examined immediately under 
a triple band (fluorescein, rhodamine, DAPI) filter. Exponentially 
growing cells treated with saponin (0.1%, 10 min) were used as control 
dead cells. 
2.5. Measurement of cell viability 
Exponentially growing HFFF2 cells at 50% confluence, in 24-well 
plates, were cultured with complete DMEM containing 8% FBS and 
varying concentrations of PI for 8 h or 28 h. Cells were scraped to 
harvest both adherent cells and floating cells, centrifuged (600 Xg, 
6 min), washed with PBS, incubated with 400 ul PBS/6 uM calcein 
AM (30 min, dark) and fluorescent intensity (FI) measured in a lu-
minescence spectrophotometer (excitation at 485 nm, emission read at 
530 nm). Positive controls were prepared untreated cells, and negative 
controls (of dead cells) were prepared by treating the cells with 0.1% 
saponin in PBS for 30 min. Triplicates were performed for each ex-
perimental condition, and the total percentage of live cells calculated 
using the formula: 
% Live cells = 100 X sample FI—FI of saponin — treated cells 
FI of untreated cells—FI of saponin — treated cells 
grown to 40%) confluence (2 days) in complete DMEM containing 
8% FBS, at which time fresh medium containing varying concentra-
tions of PI was added. Duplicates of each experimental condition 
were performed. Following culture for 8 h or 28 h, adherent cells 
were removed by scraping and the total cell population transferred 
onto glass microscope slides (cytospin, 600 rpm, 5 min) and fixed 
(100%. methanol). Cells were permeabilised by immersion in PBS con-
taining 0.2% Triton X-100 for 5 min and the TUNEL reaction was 
performed as specified by the manufacturer. Slides were mounted 
using Vectashield mounting medium containing DAPI (4.3 uM). TU-
NEL-positive cell nuclei were counted when slides were viewed under 
a fluorescein filter and are expressed as a percentage of the total 
number of nuclei counted when slides were viewed under a fluores-
cein/rhodamine/DAPI filter. 
2.7. FA CS analysis of cells treated with PI 
HFFF2 cells were seeded into 25-cm2 flasks (400 000 cells/flask) and 
cultured for 48 h in complete DMEM containing 8% FBS. The me-
dium was replaced with 4 ml of complete DMEM/8% FBS containing 
either PI (100 uM) or PDGF-BB (16.7 nM) and culture continued for 
28 h. Cells were dislodged from the plastic by scraping, harvested by 
centrifugation (600Xg, 5 min, 4°C), washed once with PBS and fixed 
by incubation in ice-cold 70% ethanol for 30 min. After a single wash 
with PBS, cells were incubated with 700 |xl propidium iodide at 4°C 
for 30 min in the dark. Samples were then analysed by flow cytometry 
using a Coulter Elite Flow cytometer. 
3. Results and discussion 
PI, P2 (minus Cys) and P3 (Cys replaced by Ser) gave 
similar dose-dependent profiles for the inhibition of PDGF-
BB-induced DNA synthesis in human fibroblasts, having EC5o 
values in the range of 5.1-7.05 uM (Fig. 1). A linear counter-
part of PI , P4, had no effect upon PDGF-BB-induced 
[3H]thymidine incorporation when tested up to 100 |J,M. We 
conclude that the presence of Cys is not important for the 
inhibitory activity of PI . This suggests that ligand dimerisa-
tion and consequent receptor dimerisation are not required, 
and that the effects of PI , P2 and P3 are mediated through 
monomeric receptor binding. This is in contrast to the mito-
genic response elicited by dimeric PDGF-BB, in which recep-
tor dimerisation is crucial in obtaining a mitogenic response 
[25]. 
During these experiments, we observed that PI added alone 
caused some cell death when used at higher concentrations. 
This may explain why the [3H]thymidine incorporation level 
observed when HFFF2 was incubated with PI at 100 u\M is 
2.6. Terminal deoxynucleotidyl transferase mediated dUTP nick-end 
labelling (TUNEL) assay 
HFFF2 cells seeded onto 24-well plates (10000 cells/well) were 
~ ~ 0 20 40 60 80 
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Fig. 1. The inhibition of PDGF-induced DNA synthesis in human 
fibroblasts by peptides derived from loop III of PDGF-BB. PI 
(filled squares), P2 (open triangles), P3 (filled triangles) or P4 (open 
squares) were added to growth-arrested HFFF2 cells in combination 
with PDGF-BB (0.5 nM). Percentage inhibition of [3H]thymidine in-
corporation was calculated relative to cells not treated with peptide. 
The results shown are the mean of triplicate determinations 
(±S.E.M.). 
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Fig. 2. The effect of PI on exponentially growing human flbroblasts. 
Immunofluorescent micrographs of HFFF2 cells; (a) treated with 
100 uM PI for 8 h (magnification X200), (b) untreated, (c) permea-
bilised by treatment with 0.1% saponin for 10 min (magnification 
X40). Cells were double-stained with ethidium homodimer (nuclei 
of dead cells stain red) and calcein (live cells stain green). Immuno-
fluorescent micrographs (magnification X 166) of the same HFFF2 
cells treated for 28 h with PI (100 uM) and dual-labelled (d) by 
DAPI (shows the total number of nuclei in blue) and (e) with the 
TUNEL assay (stains only those nuclei with fragmented DNA yel-
low/green). Less than 2% of untreated cells were TUNEL-positive 
(not shown). Arrows indicate: A, dead cell showing apoptotic mor-
phology and L, live cell. 
below that of the 0.2% FBS control, giving an apparent in-
hibition of [3H]thymidine incorporation greater than 100% 
(Fig. 1). Histological examination of cells treated with PI 
(100 |tM, 8 h) showed the presence of some dead cells, the 
majority of which exhibited a decrease in volume, membrane 
blebbing, nuclear condensation and often the presence of 
apoptotic bodies (Fig. 2a), all of which are characteristic of 
cells undergoing apoptosis [31,32]. 
Following preliminary studies, quantification of TUNEL 
staining [33] was examined following 8 h and 28 h incubation 
of cells with PI . We considered 8 h to be the shortest time 
period at which significant cell death and DNA fragmentation 
was observed and could be reliably assessed, and 28 h repre-
sented the doubling time of settled, exponentially growing 
HFFF2 cells. The total numbers of cell nuclei stained with 
DAPI (Fig. 2d) were compared with the numbers of nuclei 
containing fragmented DNA labelled at the 3'-OH end by 
fluorescein-12-dUTP (Fig. 2e). TUNEL-labelled nuclei (Fig. 
2e) appear brighter in the DAPI image (Fig. 2d) due to the 
cooperative effects of both TUNEL and DAPI fluorescence. 
The images clearly show that TUNEL-positive nuclei are 
smaller with condensed chromatin, two of the classical mor-
phological features of apoptosis. The percentage of TUNEL-
positive cells increased after incubation for 8 h and 28 h with 
PI in a dose-dependent manner (Fig. 3), reaching a maximum 
of 76% at 100 uM PI (28 h). The viability of exponentially 
growing HFFF2 cells decreased with increasing concentra-
tions of PI in a dose-dependent manner (Fig. 3), reaching a 
minimum of 8% at 100 uM PI (28 h). Analysis of the sub-G0/ 
Gi peak, representing cells with less than diploid DNA con-
tent, by flow cytometry confirmed DNA fragmentation which 
reached 48% of events for exponentially growing cells treated 
with PI (100 |0.M, 28 h), as compared to 6.8% for untreated 
cells (Fig. 4). As observed with the TUNEL assay, the sub-Go/ 
Gi peak was lower after 8 h incubation with PI , being 12%. 
No one criterion alone can be said to be indicative of apop-
tosis. We have shown that exponentially growing HFFF2 cells 
treated with PI undergo cell shrinkage, membrane blebbing, 
nuclear condensation and generation of apoptotic bodies, us-
ing different staining methods. We have also shown that PI 
induces DNA fragmentation as assessed by both TUNEL 
staining and flow cytometry and that this is time-dependent 
in exponentially growing cells. From a combination of these 
criteria, we conclude that apoptosis accounts for the major 
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Fig. 3. The influence of PI upon cell viability and DNA fragmenta-
tion in exponentially growing human flbroblasts. HFFF2 cells were 
cultured for 8 h and 28 h in the presence of varying concentrations 
of PI. Percent viability was determined by calcein staining, as de-
scribed in Section 2, after 8 h (open squares) or 28 h (open triang-
les) treatment with PI. Results are the mean of triplicate determina-
tions (S.E.M. £2.75% in all cases). TUNEL-positive cells with 
shrunken nuclei are expressed as a percentage of the total number 
of nuclei (DAPI-stained) after treatment of cells with PI for 8 h 
(filled squares) or 28 h (filled triangles). At least 350 cells were 
counted for each condition. 
Fig. 4. Flow cytometric analysis of exponentially growing human fl-
broblasts following treatment with PI. HFFF2 cells were cultured 
for 28 h with PI (100 uM) or PDGF-BB (0.5 nM), fixed, stained 
with propidium iodide and analysed by flow cytometry (15000 
events) as described in Section 2. HFFF2 cells treated for 4 h with 
sodium azide (1 M) were included as an example of the profiles pro-
duced by necrotic cells [34]. Arrow N indicates an extra population 
of cells seen in the forward/side scatter plot in necrotic cells. The 
percentage of sub-G0/Gi events is indicated for each of the DNA 
content histograms. 
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Table 1 
Inhibition of DNA synthesis in HFFF2 cells treated with PI in the presence of various growth factors 
Growth factor 
PDGF (15 ng/ml) 
EGF (1 ng/ml) 
FGF (0.5 ng/ml) 
Thrombin (4 U/ml) 
Thrombin (4 U/ml) 
FBS 8% 
Assay 
28 
28 
28 
28 
44 
28 
duration (h) EC50 inhibition 
5.27 
7.37 
2.50 
3.35 
8.00 
15.00 
(MM) S.D. 
2.30 
0.84 
0.50 
0.75 
1.00 
5.00 
EC100 inhibition (uM) 
25 
20 
6 
19 
25 
45 
This table shows the concentrations of PI which cause 50% (EC50) and 100% (EC100) inhibition of growth factor-induced [3H]thymidine incor-
poration in quiescent human dermal fibroblasts (HFFF2) stimulated with various mitogens. Linear peptide, 73RKIEIVRKK81-C (P4), which 
corresponds in amino acid sequence to PI, showed no ability to inhibit DNA synthesis in the presence of any of the mitogens used. 
proportion of cell death induced by PI , and that this phenom-
enon is cell cycle-dependent possibly reflecting the need for 
exponentially growing cells to reach the Gi/S checkpoint prior 
to apoptosis. Also, Pl-induced apoptosis occurs in exponen-
tially growing human fibroblasts in the presence of 8% FBS, 
optimal conditions for growth in which no shortage of pro-
gression factors should exist. 
Cells treated with high concentrations of PDGF-BB (16.7 
nM) show an approximate doubling of DNA fragmentation 
when compared to untreated cells, with a sub-Go/Gi peak 
representing 11.8% of total events (Fig. 4). EGF (16.7 nM) 
had no effect upon DNA fragmentation (data not shown). 
Cells treated with high concentrations of PDGF-BB (16.7 
nM) show similar morphological characteristics as those 
treated with PI including the apoptotic features of cell shrink-
age and membrane blebbing, although cells treated with the 
same concentration of EGF appeared unchanged (Fig. 5). 
Apoptosis induced by high concentrations of PDGF has pre-
viously been reported in growth-arrested murine fibroblasts 
[35]. It would seem that although normal signalling of the 
PDGF receptor leads to a mitogenic signal and even rescue 
from apoptosis [36], when present at high concentration 
PDGF may induce apoptosis. Such high concentrations may 
occur in microenvironments present in areas of platelet dep-
osition, tissue remodelling and wound healing. 
PI was able to inhibit mitogen-induced DNA synthesis in 
HFFF2 cells in the presence of PDGF-BB, EGF, FGF, 
thrombin, and FBS with effective EC50 values in the range 
of 2.5-15 uM (Table 1). 100% inhibition of proliferation 
was achieved for each of the single mitogens at <25 (J,M of 
PI and for FBS at a concentration of 45 (xM. Cells treated 
Fig. 5. Appearance of exponentially growing human fibroblasts 
(magnification X47.5) cultured for 28 h in the presence of: (a) 8%i 
FCS, (b) 8% FCS+EGF (16.7 nM), (c) 8% FCS+P1 (100 uM), (d) 
8% FCS+PDGF (16.7 nM). Cells were all at 40% confluence before 
commencement of the experiment. 
with thrombin were also pulsed between 38 and 44 h to de-
termine the effect on cells proliferating due to the secondarily 
induced responses of thrombin action (e.g. the PDGF auto-
crine pathway). Independent of the growth factor under test, 
at high concentrations of PI (25-100 |iM), all cells showed 
cell death and had the morphology of apoptotic cells, repre-
sented in Fig. 5c. 
Apoptosis is an active in vivo mechanism by which un-
wanted cells commit suicide and are subsequently removed 
by phagocytosis, thus avoiding release of intracellular con-
tents and associated necrotising inflammatory response [37]. 
Disruption of the proliferative/apoptotic equilibrium is a po-
tential therapeutic strategy from which to regulate normal and 
abnormal states of cellular proliferation during wound heal-
ing, atherosclerosis and restenosis. P I may be a useful com-
pound with which to study the induction of apoptosis in vas-
cular tissue, and may constitute a starting compound from 
which to develop further apoptosis-inducing agents. 
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